)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Modus Therapeutics
Modus Therapeutics (MODTX) investor relations material
Modus Therapeutics Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary26 Aug, 2026
Executive summary
Advanced toward key milestones, including ongoing Phase IIa study in CKD with anemia and progress in severe malaria program, with top-line data expected around year-end 2026/2027.
Strengthened financial position through successful warrant exercise, raising SEK 9.5 million before costs at a 94.8% exercise rate.
Reinforced scientific foundation with presentations at EHA2026 and EIC 2026, and submission of SEVUSMART Phase Ib malaria study manuscript.
Board refreshed with two new members and continued focus on capital-efficient operations and strategic partnerships.
Financial highlights
Q2 2026 loss after tax: TSEK 4,645 (vs. 6,066 in Q2 2025); loss per share: SEK 0.03 (vs. 0.17).
H1 2026 loss after tax: TSEK 7,927 (vs. 8,881 in H1 2025); loss per share: SEK 0.06 (vs. 0.25).
Cash flow from operations in Q2: TSEK -3,539 (vs. -3,423); cash equivalents at period end: TSEK 12,489.
Equity/assets ratio improved to 77% (vs. -197% in Q2 2025).
Shareholder equity at period end: TSEK 10,239 (vs. -6,744 in Q2 2025).
Outlook and guidance
Recruitment for Phase IIa CKD with anemia study expected to complete in Q4 2026; top-line data anticipated around year-end 2026/2027.
Company financed into Q1 2027, covering expected proof-of-concept data readout.
Continued focus on partnering and business development across all indications.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Modus Therapeutics
- Phase IIa CKD study progressed on plan, with financials bolstered by a major warrant exercise.MODTX
Q1 2026 - Initiated Phase IIa Part 2 for CKD/anemia and secured funding to support clinical progress.MODTXQ4 2025
- Secured funding through 2026 and advanced sevuparin's clinical and regulatory milestones.MODTXQ3 2025
- Phase IIa CKD anemia trial advances with funding secured and key milestones achieved.MODTXQ2 2025
- Losses narrowed as Modus advanced clinical trials and secured new bridge financing.MODTXQ3 2024
- H1 2024 loss narrowed as Modus advances sevuparin trials, with new study launch expected in Q3.MODTXQ2 2024
- Q1 2025 saw clinical milestones, improved loss, and new funding as Modus advanced sevuparin.MODTXQ1 2025
- Clinical progress and financing advances position Modus for pivotal 2025 milestones.MODTXQ4 2024
Next Modus Therapeutics earnings date
Q3 202624 Nov, 2026
Modus Therapeutics
Next Modus Therapeutics earnings date
Q3 202624 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage